Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 9 2 2019
medline: 9 2 2019
entrez: 9 2 2019
Statut: ppublish

Résumé

The additional author support information was erroneously omitted from the Supplementary Information. This has been corrected online.

Identifiants

pubmed: 30733620
doi: 10.1038/s41586-019-0959-z
pii: 10.1038/s41586-019-0959-z
doi:

Types de publication

Journal Article Published Erratum

Langues

eng

Pagination

E13

Commentaires et corrections

Type : ErratumFor

Auteurs

Norbert Hilf (N)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Sabrina Kuttruff-Coqui (S)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Katrin Frenzel (K)

BioNTech AG, Mainz, Germany.

Valesca Bukur (V)

BioNTech AG, Mainz, Germany.

Stefan Stevanović (S)

Eberhard Karls Universität Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany.

Cecile Gouttefangeas (C)

Eberhard Karls Universität Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany.
CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.

Michael Platten (M)

University Hospital Heidelberg, Heidelberg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
Medical Faculty Mannheim, Mannheim, Germany.

Ghazaleh Tabatabai (G)

Eberhard Karls Universität Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany.
University Hospital Tübingen, Tübingen, Germany.

Valerie Dutoit (V)

Geneva University Hospital, Geneva, Switzerland.

Sjoerd H van der Burg (SH)

CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Leiden University Medical Center, Leiden, The Netherlands.

Per Thor Straten (PT)

CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark.
Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

Francisco Martinez-Ricarte (F)

Vall d'Hebron University Hospital, Barcelona, Spain.

Berta Ponsati (B)

BCN Peptides SA, Barcelona, Spain.

Hideho Okada (H)

University of California, San Francisco, San Francisco, CA, USA.
Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.

Ulrik Lassen (U)

Ringhospitalet, Copenhagen, Denmark.

Arie Admon (A)

Technion - Israel Institute of Technology, Haifa, Israel.

Christian H Ottensmeier (CH)

University of Southampton, Southampton, UK.

Alexander Ulges (A)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Sebastian Kreiter (S)

BioNTech AG, Mainz, Germany.
CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.

Andreas von Deimling (A)

University Hospital Heidelberg, Heidelberg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.

Marco Skardelly (M)

University Hospital Tübingen, Tübingen, Germany.

Denis Migliorini (D)

Geneva University Hospital, Geneva, Switzerland.

Judith R Kroep (JR)

Leiden University Medical Center, Leiden, The Netherlands.

Manja Idorn (M)

Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Herlev, Denmark.
Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

Jordi Rodon (J)

Vall d'Hebron University Hospital, Barcelona, Spain.
M. D. Anderson Cancer Center, University of Texas, Houston, TX, USA.

Jordi Piro (J)

BCN Peptides SA, Barcelona, Spain.

Hans S Poulsen (HS)

Ringhospitalet, Copenhagen, Denmark.

Bracha Shraibman (B)

Technion - Israel Institute of Technology, Haifa, Israel.

Katy McCann (K)

University of Southampton, Southampton, UK.

Regina Mendrzyk (R)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Martin Lower (M)

BioNTech AG, Mainz, Germany.

Monika Stieglbauer (M)

Eberhard Karls Universität Tübingen, Tübingen, Germany.
CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.

Cedrik M Britten (CM)

BioNTech AG, Mainz, Germany.
CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Oncology R&D, GlaxoSmithKline, Stevenage, UK.

David Capper (D)

University Hospital Heidelberg, Heidelberg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
Charité, University Medicine Berlin, Berlin, Germany.

Marij J P Welters (MJP)

CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.
Leiden University Medical Center, Leiden, The Netherlands.

Juan Sahuquillo (J)

Vall d'Hebron University Hospital, Barcelona, Spain.

Katharina Kiesel (K)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Evelyna Derhovanessian (E)

BioNTech AG, Mainz, Germany.

Elisa Rusch (E)

Eberhard Karls Universität Tübingen, Tübingen, Germany.
CIMT/CIP - Association for Cancer Immunotherapy, working group Cancer Immunoguiding Program, Mainz, Germany.

Lukas Bunse (L)

University Hospital Heidelberg, Heidelberg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.

Colette Song (C)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Sandra Heesch (S)

BioNTech AG, Mainz, Germany.

Claudia Wagner (C)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Alexandra Kemmer-Bruck (A)

BioNTech AG, Mainz, Germany.

Jorg Ludwig (J)

Immatics Biotechnologies GmbH, Tübingen, Germany.

John C Castle (JC)

BioNTech AG, Mainz, Germany.
Agenus Inc, Lexington, KY, USA.

Oliver Schoor (O)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Arbel D Tadmor (AD)

TRON GmbH - Translational Oncology at the University Medical Center of Johannes Gutenberg University, Mainz, Germany.

Edward Green (E)

German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany.
Medical Faculty Mannheim, Mannheim, Germany.

Jens Fritsche (J)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Miriam Meyer (M)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Nina Pawlowski (N)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Sonja Dorner (S)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Franziska Hoffgaard (F)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Bernhard Rossler (B)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Dominik Maurer (D)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Toni Weinschenk (T)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Carsten Reinhardt (C)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Christoph Huber (C)

BioNTech AG, Mainz, Germany.

Hans-Georg Rammensee (HG)

Eberhard Karls Universität Tübingen, Tübingen, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center Partner Site Tübingen, Tübingen, Germany.

Harpreet Singh-Jasuja (H)

Immatics Biotechnologies GmbH, Tübingen, Germany.

Ugur Sahin (U)

BioNTech AG, Mainz, Germany.

Pierre-Yves Dietrich (PY)

Geneva University Hospital, Geneva, Switzerland.

Wolfgang Wick (W)

University Hospital Heidelberg, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de.
German Cancer Consortium (DKTK), German Cancer Research Center, Heidelberg, Germany. wolfgang.wick@med.uni-heidelberg.de.

Classifications MeSH